Targeted therapy is based on directly inhibiting specific intracellular driver mutations that mediate tumor cell proliferation, and randomized clinical trials have demonstrated improvements in overall survival for patients treated with inhibitors of mutated BRAF and MEK, members of the Ras-Raf-MEK-ERK mitogen-activated protein kinase signaling pathway [3-5]. Here, MAP2K7 is linked to neoplasm.